Short-term effects of transcorneal electrical stimulation on visual performance
Official title: Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation (TES) on Visual Performance in Patients With Retinitis Pigmentosa and Similar Retinal Diseases
Run by Okuvision GmbH · NCT07548944 · Data updated 2026-11-12
This study will see if a 30-minute session of transcorneal electrical stimulation with the OkuStim device produces short-term vision improvements in adults with retinitis pigmentosa or similar retinal degenerations who already use the device.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Okuvision GmbH Industry-sponsored |
| Locations | 1 site (Frankfurt am Main) |
| Status | Recruiting |
| Started | April 20, 2026 |
| Main results expected | March 2027 |
| Study ends | March 2027 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT07548944 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with clinically diagnosed retinitis pigmentosa or similar degenerative retinal disease who currently use the OkuStim system and report short-term vision changes after treatment are ideal candidates.
✕Probably not a fit
Patients who do not use OkuStim, do not notice any short-term changes after stimulation, have other ocular diseases that confound measurements, or have cognitive or medical conditions preventing participation are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label observational study enrolls adults with retinitis pigmentosa or related degenerative retinal diseases who are current users of the OkuStim system and report short-term subjective effects after treatment. Participants complete a questionnaire, undergo baseline ophthalmic tests (slit-lamp exam, best-corrected visual acuity, quick contrast sensitivity function, kinetic perimetry, microperimetry), receive a 30-minute TES session with OkuStim, and then have key vision tests repeated. After a ~3.5-hour break and a second questionnaire about perceived changes, final examinations are performed to capture any persisting short-term effects. The goal is to quantify reported immediate vision changes and contribute data toward understanding TES mechanisms.
Why it matters
Potential benefit: If successful, the study could confirm and quantify short-term vision improvements after TES and help clinicians and patients optimize symptom management and timing of therapy.
How similar studies have gone: TES has regulatory CE-mark approval for slowing longer-term progression and there are anecdotal reports of immediate subjective improvements, but short-term effects have not been systematically measured in controlled investigations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥ 18 years) with clinically diagnosed retinitis pigmentosa (RP) or other similar degenerative retinal disease * Current treatment with TES using the OkuStim® System within the intended purpose * Subjective perception of short-term effects after TES treatment * Ability and willingness to give informed consent Exclusion Criteria: * Cognitive, psychological, or linguistic limitations that prevent informed consent or proper study participation * Presence of other eye diseases (e.g., cataract, glaucoma, macular degeneration) that, in the opinion of the investigator, compromise or confound study assessments * Simultaneous participation in other clinical studies that could influence the results of the study * Severe comorbidities that could compromise patient safety or study conduct
Where it's running
-
Augenzentrum Frankfurt Prof. Koch GmbH
Frankfurt am Main, Germany Recruiting
Study contacts
- Principal investigator: Dr. med. Svenja Deuchler — Augenzentrum Frankfurt Prof. Koch GmbH
- Study coordinator: Claudia Büdel
- Email: info@azffm.de
- Phone: +49 69 7566 8880
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating OpCT-001 for treating primary photoreceptor disease
This study is testing a new treatment called OpCT-001 to see if it can safely help adults with primary photoreceptor diseases, like Retinitis Pigmentosa and Usher Syndrome, improve their vision.
-
NPI-001 for preserving photoreceptors in RP with Usher syndrome
This trial tests whether NPI-001 can slow vision loss in adults with RP linked to Usher syndrome, compared with a placebo over 24 months.
-
Registry for inherited retinal degenerative diseases
This study is creating a registry for people with rare inherited eye diseases to help track their health and experiences over time, making it easier to understand these conditions and support research.
-
Eye gene therapy for retinitis pigmentosa with a single RTx-015 injection
A single eye injection of RTx-015 is being tested to see if it helps people with retinitis pigmentosa.
-
Gene therapy SPVN20 for advanced rod-cone dystrophy
This study tests different doses of SPVN20 injected into the eye to see if it is safe and can help people with advanced rod-cone dystrophy.
-
Pitavastatin in PLGA Nanoparticles for Retinitis Pigmentosa safety test
This Phase 1 study tests whether an intravenous pitavastatin nanoparticle formulation is safe for adults with retinitis pigmentosa.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.